Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 41 (Search time: 0.007 seconds).
previous
1
2
3
4
...
5
next
Item hits:
Preview
Issue Date
Title
Author(s)
2016
ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment
Eadie, L.
;
Hughes, T.
;
White, D.
;
New Directions in Leukaemia Research 2016 Meeting (NDLR) (16 Mar 2016 - 19 Mar 2016 : Noosa, QLD)
2013
STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner
Schafranek, L.
;
Nievergall, E.
;
Powell, J.
;
Hiwase, D.
;
White, D.
;
Hughes, T.
;
Leclercq, T.
2010
Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial
Yeung, D.
;
Osborn, M.
;
White, D.
;
Branford, S.
;
Haswell, L.
;
Slader, C.
;
Issa, S.
;
Hiwase, D.
;
Hertzberg, M.
;
Schwarer, A.
;
Filshie, R.
;
Arthur, C.
;
Kwan, Y.
;
Forsyth, C.
;
Ross, D.
;
Mills, A.
;
Grigg, A.
;
Hughes, T.
;
Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2017
Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia
Sopper, S.
;
Mustjoki, S.
;
White, D.
;
Hughes, T.
;
Valent, P.
;
Burchert, A.
;
Gjertsen, B.
;
Gastl, G.
;
Baldauf, M.
;
Trajanoski, Z.
;
Giles, F.
;
Hochhaus, A.
;
Ernst, T.
;
Schenk, T.
;
Janssen, J.
;
Ossenkoppele, G.
;
Porkka, K.
;
Wolf, D.
2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Ross, D.
;
Pagani, I.
;
Shanmuganathan, N.
;
Kok, C.
;
Seymour, J.
;
Mills, A.
;
Filshie, R.
;
Arthur, C.
;
Dang, P.
;
Saunders, V.
;
Braley, J.
;
Yong, A.
;
Yeung, D.
;
White, D.
;
Grigg, A.
;
Schwarer, A.
;
Branford, S.
;
Hughes, T.
2016
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
Nievergall, E.
;
Reynolds, J.
;
Kok, C.
;
Watkins, D.
;
Biondo, M.
;
Busfield, S.
;
Vairo, G.
;
Fuller, K.
;
Erber, W.
;
Sadras, T.
;
Grose, R.
;
Yeung, D.
;
Lopez, A.
;
Hiwase, D.
;
Hughes, T.
;
White, D.
2015
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy
Yeung, D.
;
Tang, C.
;
Vidovic, L.
;
White, D.
;
Branford, S.
;
Hughes, T.
;
Yong, A.
2012
Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
Wang, J.
;
Hughes, T.
;
Kok, C.
;
Saunders, V.
;
Frede, A.
;
Groot Obbink, K.
;
Osborn, M.
;
Somogyi, A.
;
D'Andrea, R.
;
White, D.
2014
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
Eadie, L.
;
Hughes, T.
;
White, D.
2013
Which TKI? An embarrassment of riches for chronic myeloid leukemia patients
Hughes, T.
;
White, D.
Discover
Author
5
Engler, J.
5
Leclercq, T.
5
Nievergall, E.
5
Ross, D.
4
D'Andrea, R.
4
Osborn, M.
4
Sadras, T.
4
Schafranek, L.
4
Vaz de Melo, J.
4
Watkins, D.
.
< previous
next >
Subject
22
Humans
18
Leukemia, Myelogenous, Chronic, B...
16
Pyrimidines
11
Imatinib Mesylate
11
Protein Kinase Inhibitors
10
Antineoplastic Agents
10
Piperazines
9
Benzamides
9
Female
9
Male
.
next >
Date issued
3
2018
6
2017
4
2016
2
2015
2
2014
10
2013
3
2012
4
2011
7
2010